Panangin 1×10 ml vial

452 mg potassium aspartate (anhydrous)  400 mg magnesium aspartate (anhydrous) per 10 ml vial

Active Ingredients:

Kalium Aspartate, Magnesium Aspartate

Therapeutic actions:

Stimulates myocardium’s metabolism, increases tolerance to digitalics, has anti-arrythmic effect.


pectoral angina (as adjuvant), arrhythmias in myocardium infarct and postinfarct conditions, arrhythmias provoked by the intolerance to digitalics, digitalic intoxication. Cardiac rhythm disorders (tahiarrhythmias, ventricular extrasystoles).

Contraindications and cautions:

acute and chronic renal insufficiency. hyperpotassiemia and with disorder of the atrioventricular conductivity (cataplexy). Panangin is not recommended with patients who have rhythm disorderes associated with atrio-ventricular block.

Adverse effects:

The following are some of the side effects that are known to be associated with this medicine. Because a side effect is stated here, it does not mean that all people using this medicine will experience that or any side effect.
Nausea, vomiting, diarrhea, stomach ache, ulcer, gastrointestinal hemorrhage, wind, dry mouth, bragicardia, decrease in blood pressure, phlebit, vein thrombosis, skin irritation, hyporeflexia, vertigo, paresthesia, myasthenia, asthenia, sweating. If injected rapidly can cause hyperkaliemia, hypermagnesemia.
The side effects listed above may not include all of the side effects reported by the drug’s manufacturer.


Tell your doctor or pharmacist what medicines you are already taking, including those bought without a prescription and herbal medicines, before you start treatment with this medicine.
Amplifies negative effect of antiarrhythmic means. Beta-blocker, cyclosporine, potassium-sparing diuretic, heparin, inhibitors of APF, NSAID can increase risk of hyperkaliemia. General anesthetic drugs can intensify inhibitory action on CNS. During simultaneous use with athracuronim, dekametonim, succinylchloride and succsametoniem there is a possibility of increase in neuromuscular blockade. Binding and covering agents lower absorption in gastrointestinal tract. Pharmaceuticaly Asparcam can be combined with solutions of heart glycosides.